Patent ID: 9213032
Filing Date: 2015-12-15
Classification: A61K,C07K,C12Q,G01N

Abstract:
1. A method of identifying a subject suitable for treatment with an anti-c-Met antibody or antigen-binding fragment thereof that specifically binds to an epitope within a SEMA domain of a c-Met protein, comprising: (1) determining the presence of LRIG1 in a cell sample from the subject so as to allow LRIG1-mediated c-Met degradation; (2) determining that the subject is suitable for treatment with the anti-c-Met antibody or antigen-binding fragment thereof when LRIG1 is present in the cell sample; and (3) administering the anti-c-Met antibody or antigen-binding fragment thereof to the subject determined to be suitable for treatment, wherein the anti-c-Met antibody or antigen-binding fragment thereof comprises SEQ ID NOs: 1-3, 10, 11, and 13, specifically binds to an epitope having 5 to 19 consecutive amino acids of SEQ ID NO: 71 that includes the amino sequence of SEQ ID NO: 73 (EEPSQ) and promotes LRIG1-mediated c-Met degradation.